直升机转运接受V-V ECMO的COVID-19患者:首例病例报告
本文报告首例接受V-V ECMO的COVID-19患者通过直升机转运至ECMO中心。患者为45岁男性,有类风湿关节炎史并接受免疫抑制剂治疗,因COVID-19进展为呼吸衰竭,在转出医院住院第10天插管,次日ECMO团队在转出医院启动V-V ECMO后经直升机转运,飞行时间7分钟。患者入住ICU并接受tocilizumab治疗,住院第31天出院,无显著后遗症。文章讨论了COVID-19患者ECMO院际转运的安全因素及直升机转运中的医护人员与患者安全。
要点
- 45岁男性COVID-19患者,有类风湿关节炎史并接受免疫抑制剂治疗,呼吸衰竭进行性加重,住院第10天插管,次日请求ECMO转运。
- ECMO团队穿戴个人防护装备(N95口罩、手套、隔离衣和面屏)在转出医院启动V-V ECMO,随后经直升机安全转运,飞行时间7分钟。
- 患者转入ECMO中心ICU后接受tocilizumab治疗,住院第31天出院,无显著后遗症。
- 为缩短转运时间,直升机是合适选择;因大流行导致可接收转诊的ECMO中心数量有限,此类患者的安全长途院际转运值得关注。
- 本文为首例报告,讨论了COVID-19患者ECMO院际转运及直升机转运中医护人员与患者安全的重要因素。
适用人群与场景
- 接受V-V ECMO的COVID-19相关急性呼吸窘迫综合征患者,需院际转运至ECMO中心。
- 本例为45岁男性,有类风湿关节炎病史并接受免疫抑制剂治疗。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 第一步:ECMO团队穿戴个人防护装备(N95口罩、手套、隔离衣和面屏)。
- 第二步:在转出医院启动V-V ECMO。
- 第三步:经直升机将患者转运至ECMO中心,飞行时间7分钟。
- 第四步:入住ECMO中心ICU,接受tocilizumab治疗。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 病例报告:1例45岁男性COVID-19患者,有类风湿关节炎史并接受免疫抑制剂治疗,因呼吸衰竭进行性加重,在转出医院住院第10天插管,次日由ECMO团队在转出医院启动V-V ECMO后经直升机转运,飞行时间7分钟,入住ICU并接受tocilizumab治疗,住院第31天出院,无显著后遗症。
证据类型、等级与局限
- 证据类型:病例报告。
- 原文未述局限性。
对床旁实践的改变
- 本文报告首例直升机转运接受V-V ECMO的COVID-19患者,提示在需缩短转运时间且可接收的ECMO中心有限时,直升机转运可作为选择;转运中需关注医护人员与患者安全。
- 适用人群为需院际转运至ECMO中心的接受V-V ECMO的COVID-19患者;原文未提及不适用人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Some coronavirus disease 2019 (COVID-19) patients develop rapidly progressive acute respiratory distress syndrome and require veno-venous extracorporeal membrane oxygenation (V-V ECMO). A previous study recommended the transfer of ECMO patients to ECMO centers. However, because of the pandemic, a limited number of ECMO centers are available for patient transfer. The safe long-distance interhospital transport of these patients is a concern. To minimize transportation time, helicopter use is a suitable choice. We report the first case of a COVID-19 patient on V-V ECMO, transferred to our ECMO center by helicopter. A 45-year-old man with rheumatoid arthritis history, treated with immunosuppressants, presented with fever and sore throat. He was diagnosed with COVID-19 following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test result and was subsequently prescribed favipiravir. However, his respiratory failure progressively worsened. On day 10 of hospitalization at the previous hospital, he was intubated, and we received a request for ECMO transport on the next day. The ECMO team, who wore personal protective equipment (N95 respirators, gloves, gowns, and face shields), initiated V-V ECMO in the referring hospital and safely transported the patient by helicopter. The flight time was 7 min. He was admitted to the intensive care unit of our hospital and received tocilizumab. He was discharged on hospital day 31 with no significant sequelae. In this case report, we discuss important factors for the safe and appropriate interhospital transportation of COVID-19 patients on ECMO as well as staff and patient safety during helicopter transportation.
参考来源
- Imaeda T, Hattori N, Abe R, et al. Interhospital transportation of a COVID-19 patient undergoing veno-venous extracorporeal membrane oxygenation by helicopter. Am J Emerg Med. 2020. PMID: 33067063. doi:10.1016/j.ajem.2020.09.089
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。